Blucora Inc. (BCOR) Tops Q3 EPS by 11c

Blucora Inc. (NASDAQ: BCOR) reported Q3 EPS of ($0.26), $0.11 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $174.2 million versus the consensus estimate of $165.88 million.

GUIDANCE:

Blucora Inc. sees FY2021 EPS of $1.65-$1.73, versus the consensus of $1.64. Blucora Inc. sees FY2021 revenue of $870-876 million, versus the consensus of $867 million.

For earnings history and earnings-related data on Blucora Inc. (BCOR) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance